"Genentech’s commitment to basic biology and innovation is fundamental to novel drug development."
I joined Genentech in 2016. Prior to Genentech, I was a faculty member at the University of Chicago studying immune tolerance and autoimmune disease. I was fascinated by tumor immunology as tumors represent a unique “self” to the immune system. The recent success of cancer immunotherapy has been revolutionizing the field, and I was thrilled to join Genentech to develop novel immunotherapies that could have direct impact on patients.
Cell Rep. 2016 Oct 4;17(2):387-398.
My lab focuses on evaluating the efficacy, pharmacokinetics, pharmacodynamics, mechanism of action, and combinatorial therapeutic strategies of small molecules and biologics against select targets in cancer immunotherapy. We utilize and develop various mouse models of tumor immunology. We work closely with our discovery colleagues in Cancer Immunology to inform preclinical target validation and molecule selection.